The U.S. measles cases 2026 market is a ladder of ten CDC case-count thresholds running from 3,000 cases up through 12,500. The year it prices is already the worst for measles in the United States since 1991, with 2,566 confirmed cases through August 13, 2026, past the 2,289 logged across all of 2025. The board carries roughly $8.5M in cumulative volume across Kalshi and Polymarket, and the live board above ranks the current price on every rung. It resolves December 31, 2026.
The U.S. measles cases 2026 market is a ladder of ten CDC case-count thresholds, and the year it prices has already become the worst measles year in the United States since 1991. The CDC counted 2,566 confirmed cases through August 13, 2026, clearing the 2,289 recorded across all of 2025 with four and a half months still on the calendar. The rungs now run from 3,000 cases up through 3,500, 4,000, 4,500, 5,000, 6,000, 7,500, 8,000, 10,000, and 12,500, and the board carries roughly $8.5M in cumulative volume across Kalshi and Polymarket. The live board above ranks the current cross-platform price on every rung.
Because this is a ladder, there is no single favored candidate to name. Each rung is its own contract asking whether the confirmed national total reaches at least that many cases by year end, and the rungs are listed separately on each platform before being grouped here into one curve. The empty candidates list is expected for a threshold board rather than a defect.
The rung set itself has moved this year. The 2,150 threshold that anchored the bottom of this board in June has been overtaken by the running count and left the ladder, while 3,500 and 4,500 rungs were added in the band where the year-end total is genuinely in question. The board now opens on the 4,500 line, which is where the market's central estimate currently sits.
Reading the curve is straightforward. Prices sit high on the low thresholds the count has all but banked and fall as the rungs climb toward totals the market treats as long shots. Where both Kalshi and Polymarket list the same rung, the two prices side by side show whether the books agree at that level. Several rungs are listed on only one of the two, so a blank on one side means there is no contract there, not a price of zero.
The arithmetic is the starting point. From 2,566 confirmed cases, the 4,000 rung needs another 1,434 cases before December 31 and the 6,000 rung needs 3,434. Through the first 32 weeks of 2026 the national count ran 92% ahead of the same stretch of 2025, and that pace is what the middle of the ladder is pricing.
Geography does most of the work. The CDC has logged 38 outbreaks in 2026 and roughly 94% of confirmed cases are outbreak-associated, so the total moves in clusters rather than a steady drip. South Carolina leads with about 670 cases, Utah is running the largest active outbreak at more than 500, and Pennsylvania, Texas, and Virginia each sit in the 175 to 220 range. A single introduction into an undervaccinated community is what lifts several rungs at once, and a quiet month flattens the top of the ladder.
Vaccination coverage sits underneath all of it. About 93% of 2026 cases involved people who were unvaccinated or whose status was unknown, and roughly 68% were 19 or younger. Containment speed matters just as much: how fast contact tracing and isolation reach a cluster decides whether it stays a dozen cases or compounds into the hundreds that Utah and South Carolina have each produced. The hospitalization rate has run near 7% in 2026, down from 11% in 2025.
One policy catalyst hangs over the fall. The Pan American Health Organization's regional verification commission has pushed its review of U.S. measles elimination status to November 2026, with genetic evidence of sustained domestic transmission tracing back to the January 2025 West Texas outbreak. That review does not resolve this market, but it concentrates attention and response resources on exactly the chains the ladder is counting. Traders pricing the same public-health risk surface also trade the pandemic 2026 odds alongside this board.
Timing is the quiet factor. The count only climbs, so a rung that clears stays cleared, and a late-autumn cluster still counts against the December 31 line.
The market resolves December 31, 2026, against the U.S. measles case count for the calendar year as published by the Centers for Disease Control and Prevention. Each rung resolves Yes if the confirmed national total reaches or exceeds that rung's number and No if it does not. Because the tally accumulates over the year, a threshold that has already been passed stays settled at Yes, and the only open question on any rung is whether the remaining months carry the count far enough.
For adjacent public-health and tail-risk contracts, compare the Ebola pandemic 2026 odds and the natural disaster 2026 odds, both of which price low-probability threshold events on the same calendar-year clock. Browse the full tech prediction markets hub for more science and biotech boards trading across Kalshi and Polymarket.
Resolves December 31, 2026, against the U.S. measles case count for the calendar year as reported by the Centers for Disease Control and Prevention. The market is a ladder of fixed thresholds running from 3,000 cases through 12,500 cases; each rung resolves Yes if the confirmed national total reaches or exceeds that rung's number and No if it does not. The CDC's published full-year tally is the source of truth. Because the count accumulates, a rung whose threshold has already been cleared stays settled at Yes, and any platform-specific tie-breaking or void rules apply if the official count is unavailable at resolution.
The market is a ladder of CDC case-count thresholds from 3,000 up through 12,500, each priced separately on Kalshi and Polymarket. As of August 17, 2026 the board's center of gravity sits on the 4,500 rung, with the low thresholds near settled and the 10,000-and-up rungs trading in single digits. The live board above carries the current price on every rung across roughly $8.5M in cumulative volume.
The CDC confirmed 2,566 measles cases through August 13, 2026, the highest annual U.S. total since 1991. That figure already exceeds the 2,289 cases recorded across all of 2025, with 38 outbreaks logged and about 94% of cases outbreak-associated.
It resolves December 31, 2026, against the U.S. measles case count for the calendar year as reported by the CDC. Each rung resolves Yes if the confirmed national total reaches or exceeds that threshold, and the count only climbs, so a cleared rung stays settled at Yes.
Both Kalshi and Polymarket list case-count thresholds for 2026, and Prediction Genius groups them into one ladder so the two books can be compared on each shared rung, including the 3,000, 4,000, and 10,000 levels. Several rungs such as 4,500 and 6,000 are listed on only one platform, so those show a single price rather than a cross-platform pair.
It is a threshold ladder, not a multi-candidate race, so the data renders as a row of case-count rungs from 3,000 to 12,500 rather than named candidates. The empty candidates list is expected for a ladder market, not an error.
Watch the weekly CDC case updates and the Utah and South Carolina outbreak chains, since a new multi-state cluster is what lifts the 6,000-and-up rungs. The Pan American Health Organization's review of U.S. measles elimination status in November 2026 is the other date on the calendar before the December 31, 2026 resolution.